ASCPT showcases the best in clinical pharmacology and translational science, bringing together the most influential industry professionals. The 2025 Annual Meeting theme, Patient-Centric Clinical Pharmacology: A Journey from Discovery to Recovery, highlights the fundamental principle that patients are the most important stakeholders in health care. Each session will embody the spirit of patient-centricity across the full DDRU continuum from discovery to recovery so you can amplify your impact. 

As an ASCPT Ambassador Partner, we look forward to hosting attendees for a one-of-a-kind Learning Lab.

Title: Recipe for Success: How Integrated MIDD & AI Approaches Can Accelerate Obesity Drug Development

Abstract:
The global obesity drug market is projected to grow to $37.94 billion by 2032, driven largely by the drugs currently in development. The pace of development is fierce, and sponsors aiming to compete must leverage all available tools to optimize efficacy, minimize side effects, and accelerate development timelines. Model-informed drug development (MIDD) and artificial intelligence (AI) can assist in achieving these goals.

In this one-hour Learning Lab, attendees will follow the development process of a drug candidate targeting obesity, from the early stages of discovery through pre-clinical and clinical development. The panel of experts will explain the technology and methodologies available to design and prioritize drug candidates, identify dosing strategies that optimize efficacy and minimize safety concerns, and design protocols that increase the likelihood of clinical success and regulatory approval. They will also discuss how predictions generated in earlier stages can inform MIDD choices and support decision-making in later phases of development.

Attendees will have the opportunity to ask questions throughout the interactive panel discussion, while they enjoy a light lunch.

Date: Thursday, May 29th
Time: 12:15 – 1:15 PM EDT
Location: National Harbor Room 6/7

Panelists:

• Mike (Ke) Liu, Ph.D., Director, Clinical Pharmacology and Pharmacometrics, Structure Therapeutics
• David C. Sperry, Ph.D., Executive Director, Synthetic Molecule Design & Development, Eli Lilly & Co.
• Amparo de la Peña, Ph.D., Vice President, Pharmacometric Services, Simulations Plus
• Scott Siler, Ph.D., Chief Science Officer, QSP, Simulations Plus
• Maxime Le Merdy, Ph.D., Director, PBPK Research & Collaborations, Simulations Plus
• Sandra Suarez-Sharp, Ph.D., President, Regulatory Center of Excellence, Simulations Plus

Moderator:

• Jill Fiedler-Kelly, MS, FISoP, President, CPP Services, Simulations Plus

Join us and meet our Simulations Plus experts.  We hope to see you there!

Can’t Miss Presentations!

TITLE: Quantitative Systems Toxicology (QST) Modeling Using BIOLOGXsym and Mechanistic Toxicity Data from a Biomimetic Liver Microphysiology System Predicts Biologics-Induced Liver Injury (BILI) for Multiple Large Molecules (Recipient of Top Poster Ribbon from ASCPT)
PRESENTER: Dr. James Beaudoin, Sr. Scientist
DATE/TIME: Thursday, May 29, 2025 5:00pm – 6:30pm

Simulations Plus Staff in Attendance: 

• Heather Squire – Director, Business Development, Services 
• Andrew Mueller – Director, Business Development
• Maxime Le Merdy Ph.D. – Director, Research and Collaborations
• Jill Fiedler-Kelly – President, Clinical Pharmacology & Pharmacometrics Solutions
• Amparo de la Peña, Ph.D. – Vice President, Pharmacometric Services
• Qi (Joy) Yang, Ph.D. – Assistant Director of Pharmacometrics
• Yu-Nien (Tom) Sun, Ph.D. – Vice President, Strategic Consulting Services
• Steven Chang, M.S. – President, Quantitative Systems Pharmacology
• Lisl Shoda, Ph.D. – Vice President and Director of Immunology
• James J. Beaudoin, Ph.D. – Senior Scientist, Quantitative Systems Pharmacology
• Anjali Mittal, Ph.D. – Scientist II, Quantitative Systems Pharmacology
• Sandra Suarez Sharp, Ph.D. – President, Regulatory Strategies Center of Excellence
• Scott Q. Siler Ph.D. – Chief Science Officer, QSP